Hemophagocytic Lymphohistiocytosis Completed Phase 2 Trials for Melphalan (DB01042)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

Indication	Status	Phase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00176865	Stem Cell Transplant for Immunologic or Histiocytic Disorders	Treatment	Alemtuzumab (DB00087) Antilymphocyte immunoglobulin (horse) (DB09312) Cyclosporine (DB00091) Fludarabine (DB01073) Human immunoglobulin G (DB00028) Melphalan (DB01042) Mycophenolate mofetil (DB00688)